On June 10, 2024, Corealis Pharma inaugurated the expansion of its facilities nestled in the heart of Laval’s Biotech City. This expansion, the result of an investment exceeding $10 million, extends the premises of the Quebec-based company from 33,000 to 63,000 square feet, facilitating the installation of new state-of-the-art laboratories.

“My co-founders and I are immensely proud today to inaugurate these state-of-the-art laboratories. These facilities will bolster our research and development capabilities for new drugs, catering to global growth and enhancing our market presence,” said Yves Roy, president, Corealis.

Established in 2005 by three scientists—Yves Roy, Patrick Gosselin, and Yves Mouget—the Laval-based company swiftly garnered the trust of small and medium-sized biotechs globally, as well as major pharmaceutical entities, to emerge as one of the world’s foremost Contract Research and Development Organizations (CRO/CDMOs).

In 2022, to expedite its expansion, Corealis forged a partnership agreement with the CDPQ and Archimed a global investment firm focused on healthcare industries. With a clientele predominantly located in New England and California, alongside various other regions worldwide, the company recorded a 20% increase in sales for 2023.

In addition to fostering its workforce expansion, the new space will enable Corealis Pharma to expedite:

• Advancements in formulation development and manufacturing of oral solid dosage forms
• Early-stage projects
• Analytical method development
• Integration of state-of-the-art analytical and formulation equipment
• The pace and scale of drug research and development
• Expanded clinical trial material manufacturing and packaging

The company said the inauguration of its new facilities marks the realization of a three-stage strategic plan aimed at attaining the company’s primary objective: to emerge as the global benchmark in the development of oral solid dosage form formulations, thereby reinforcing Quebec’s status as a center of excellence in biotechnology.